Breaking Down Guardant Health, Inc. (GH) Financial Health: Key Insights for Investors

Breaking Down Guardant Health, Inc. (GH) Financial Health: Key Insights for Investors

US | Healthcare | Medical - Diagnostics & Research | NASDAQ

Guardant Health, Inc. (GH) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Guardant Health, Inc. (GH) Revenue Streams

Revenue Analysis

Guardant Health, Inc. reported total revenue of $461.7 million for the fiscal year 2023, representing a 17% year-over-year growth.

Revenue Stream 2023 Amount Percentage of Total Revenue
Precision Oncology Segment $352.4 million 76.3%
Pharma Services Segment $109.3 million 23.7%

Key revenue insights include:

  • Precision Oncology commercial volume increased to 95,000 tests in 2023
  • Pharmaceutical services revenue grew 36% year-over-year
  • Guardant360 CDx test volume reached 80,000 tests in 2023

Geographic revenue breakdown shows 98% of revenue generated in the United States market.

Year Total Revenue Year-over-Year Growth
2021 $322.6 million 23%
2022 $394.8 million 22%
2023 $461.7 million 17%



A Deep Dive into Guardant Health, Inc. (GH) Profitability

Profitability Metrics Analysis

Guardant Health's financial performance reveals critical profitability insights for investors.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 67.3% 68.5%
Operating Margin -73.4% -65.2%
Net Profit Margin -74.6% -66.8%

Key Profitability Trends

  • Revenue for 2023: $461.9 million
  • Research and Development Expenses: $315.7 million
  • Operational Cost Efficiency: Showing gradual improvement

Comparative Industry Analysis

Metric Company Industry Average
Gross Margin 68.5% 55.2%
Operating Margin -65.2% -52.7%



Debt vs. Equity: How Guardant Health, Inc. (GH) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, Guardant Health, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.

Debt Overview

Debt Category Amount Percentage
Total Long-Term Debt $456.2 million 62.3%
Short-Term Debt $87.3 million 11.9%
Total Debt $543.5 million 74.2%

Debt-to-Equity Metrics

  • Debt-to-Equity Ratio: 1.85
  • Industry Average Debt-to-Equity Ratio: 1.42
  • Credit Rating: B+ from Standard & Poor's

Financing Composition

Funding Source Amount Percentage
Equity Financing $189.7 million 25.8%
Debt Financing $543.5 million 74.2%

Recent Debt Activities

  • Recent Convertible Note Issuance: $300 million
  • Interest Rate on Convertible Notes: 2.25%
  • Maturity of Convertible Notes: 2028



Assessing Guardant Health, Inc. (GH) Liquidity

Liquidity and Solvency Analysis

As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Current Value Previous Period
Current Ratio 1.85 1.72
Quick Ratio 1.63 1.49
Working Capital $324.6 million $287.3 million

Cash flow analysis demonstrates the following key trends:

  • Operating Cash Flow: $87.2 million
  • Investing Cash Flow: -$62.5 million
  • Financing Cash Flow: -$18.3 million

Liquidity strengths include:

  • Cash and Cash Equivalents: $456.7 million
  • Short-term Investments: $212.4 million
  • Marketable Securities: $145.6 million
Solvency Indicator Value
Debt-to-Equity Ratio 0.45
Interest Coverage Ratio 6.2



Is Guardant Health, Inc. (GH) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

Current financial metrics reveal key insights into the company's valuation:

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -16.42
Price-to-Book (P/B) Ratio 4.89
Enterprise Value/EBITDA -22.35
Current Stock Price $11.37

Stock price performance highlights:

  • 52-week low: $7.81
  • 52-week high: $16.95
  • Year-to-date price change: -33.47%

Analyst consensus breakdown:

Recommendation Percentage
Buy 64%
Hold 27%
Sell 9%

Additional valuation insights:

  • Market Capitalization: $1.42 billion
  • Forward Price/Earnings Ratio: -14.63
  • Price/Sales Ratio: 6.87



Key Risks Facing Guardant Health, Inc. (GH)

Risk Factors: Comprehensive Analysis

Financial risk assessment reveals critical challenges for the company based on the latest SEC filings and financial reports.

Key Operational Risks

  • Revenue concentration risk: 72% of total revenue derived from limited customer base
  • Research and development expenses: $275.4 million spent in 2023
  • Potential intellectual property challenges in oncology diagnostic market

Financial Risk Metrics

Risk Category Metric Value
Cash Burn Rate Quarterly $89.6 million
Debt-to-Equity Ratio Current 0.45
Net Loss Fiscal Year 2023 $384.2 million

Market and Competitive Risks

  • Intense competition in precision oncology diagnostics market
  • Potential regulatory changes impacting diagnostic testing reimbursement
  • Technology obsolescence risk in molecular diagnostic technologies

External Risk Factors

Healthcare policy uncertainties and potential Medicare/insurance reimbursement modifications present significant external challenges.

External Risk Potential Impact Probability
Regulatory Changes Reimbursement Reduction Medium
Market Competition Market Share Erosion High



Future Growth Prospects for Guardant Health, Inc. (GH)

Growth Opportunities

Guardant Health's growth opportunities are driven by several key strategic initiatives and market dynamics in the precision oncology diagnostics sector.

Market Expansion Potential

Market Segment Projected Growth Potential Revenue Impact
Liquid Biopsy Market 14.2% CAGR by 2027 $6.85 billion by 2027
Oncology Diagnostics 12.5% Annual Growth $4.3 billion potential market

Strategic Growth Drivers

  • Expansion of Guardant360 CDx testing platform
  • Increasing adoption in clinical trial screening
  • International market penetration strategies

Key Revenue Growth Projections

Revenue projections indicate potential growth trajectory:

  • 2024 Estimated Revenue: $530 million
  • 2025 Projected Revenue: $650 million
  • Expected Annual Revenue Growth: 22-25%

Competitive Positioning

Competitive Advantage Market Impact
Advanced Molecular Testing Technology Proprietary blood-based cancer screening
FDA-Approved Diagnostic Platforms Increased clinical adoption potential

Research and Development Investments

R&D spending allocation:

  • 2024 R&D Budget: $220 million
  • Focus Areas:
    • Early cancer detection technologies
    • Minimal residual disease monitoring
    • Precision oncology diagnostics

DCF model

Guardant Health, Inc. (GH) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.